“In a 711-participant randomized phase 2b trial of heart failure with preserved or mildly reduced ejection fraction, 48 weeks of mitiperstat did not improve symptoms, six-minute walk distance, or secondary endpoints versus placebo, although safety was generally similar.”

0.9908 under ledger-default@0.3.0 at snapshot 27745.

What was asked, and where it stands. Provisional until audited.

Review 75% done · 25% counted in review coverage · 50% by the claims' own author only (1 claim, 4 checks)

Share:

Checked in Galedra: score 0.99, strongly supported · not yet reviewed by anyone else “In a 711-participant randomized phase 2b trial of heart failure with preserved or mildly reduced ejection fraction, 48 weeks of mitiperstat did not improve symptoms, six-minute walk distance, or…” https://galedra.org/investigations/01a0eaa5-7c4d-7c72-9b26-e1b220e3683d

“In a 711-participant randomized phase 2b trial of heart failure with preserved or mildly reduced ejection fraction, 48 weeks of mitiperstat did not improve symptoms, six-minute walk distance, or secondary endpoints versus placebo, although safety was generally similar.”

Supported · 0.9908 under ledger-default@0.3.0 at snapshot 27745 · review checks 1 of 4 · provisional until audited.

3 of 4 review checks done · 1 counted · 2 by the author only

See the evidence · Claim card